KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

J Capdevila, S Tafuto, M Krogh, A Teulé, R Garcia-Carbonero, H-J Klümpen, B Cremer, I Sevilla, B Eriksson, E Tabaksblat, J-P Metges, N S Reed, J Schrader, V Navarro, V Valentí, J Hernando, A M Colao, L Vestermark, C Carnaghi, U P Knigge, P Jimenez-Fonseca, M Benavent, J de Vos-Geelen, M Venerito, A Von Werder, H Jann, A Rinke, D Smith, D Hörsch, N Starling, P Ruszniewski, E Baudin, F-X Caroli-Bosc, J L Manzano, M Martín, A Scarpa, R T Lawlor, C Ragulan, H Ps, A Sadanandam, A Carmona-Bayonas, R Salazar

ESMO Open 10(12) 105922

PMID41337860
PMCIDPMC12720089
DOI10.1016/j.esmoop.2025.105922
发表日期2025-12-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. PATIENTS AND METHODS: SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS1). RESULTS: Patients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS1 was 71.4% [95% confidence interval (CI) 59.4% to 81.6%] and 61.8% (95% CI 49.2% to 73.3%) (odds ratio 0.65, 95% CI 0.32-1.32) with a median PFS1 of 19.4 versus 22.7 months for everolimus and STZ/5-FU, respectively. STZ/5-FU achieved a significantly higher overall response rate in first-line (11.6% versus 30.3%, P = 0.012) and second-line (30.6% versus 9.1%, P = 0.072) treatments. No differences were shown in overall survival (median 61.7 versus 50.6 months in everolimus first and STZ/5-FU first, respectively; hazard ratio 1.43, 95% CI 0.86-2.37). Discontinuations of everolimus were more frequent. CONCLUSION: STZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2 Survival outcomes in arm A (everolimus followed by STZ/5-FU) and arm B (STZ/5-FU followed by everolimus). (A) Kaplan–Meier analysis of progression-free survival (PFS) to first treatment (PFS 1 ). (B) Multivariable hazard analysis of PFS 1 to first treatment assigned in selected subgroups. (C) Kaplan–Meier analysis of PFS to second treatment (PFS 2 ). (D) Multivariable hazard analysis of PFS 2 to first treatment assigned in selected subgroups. (E) Kaplan–Meier analysis of overall survival. (F) Multivariable hazard analysis of OS in selected subgroups. The gold dots and error bars represent the HR and 95% CIs. 5-FU, 5-fluorouracil; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; Eve, everolimus; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; STZ, streptozotocin.

A

PFS 1

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS 2

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

OS

Figure 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 CONSORT diagram showing patient allocation. 5-FU, 5-fluorouracil; ITT, intention-to-treat; pts, patients; SP, safety population; STZ, streptozotocin.
非 KM Figure
Figure 3Figure 3 Objective response rate (ORR) in arm A (everolimus followed by STZ/5-FU) and arm B (STZ/5-FU followed by everolimus). (A) Waterfall plot for overall response rate (ORR) to everolimus and streptozotocin (STZ) plus 5-fluorouracil (5-FU) as first assigned treatment reporting the percentage change from baseline in the sum of the longest diameters of target lesions. (B) Multivariable analysis of ORR to first treatment assigned in selected subgroups. The gold dots and error bars represent the odds ratio and the 95% confidence interval. (C) Waterfall plot for ORR to everolimus and STZ plus 5-FU as second assigned treatment. (D) Multivariable analysis of ORR to the second treatment assigned in selected subgroups. Arm A (sequence everolimus/STZ and 5-FU) in blue and arm B (sequence STZ and 5-FU/Everolimus) in red. 5-FU, 5-fluorouracil; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; ECOG-PS, Eastern Cooperative Oncology Group performance status; NE, not evaluable; OR, odds ratio; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; STZ, streptozotocin.
非 KM Figure
Figure 4Figure 4 Safety in arm A (everolimus followed by STZ/5-FU) and arm B (STZ/5-FU followed by everolimus). Treatment-related adverse events reported throughout the study period, including most frequent events (cut-off >5%) and those of special interest such as hematologic toxicities in first line (A) and second line (B). P value on the right of the events that had statistically significant differences in rates between study arms (Fisher’s exact test).
非 KM Figure